Total Payments
$9,622
2024 Payments
$1,727
Companies
15
Transactions
576
Medicare Patients
784
Medicare Billing
$714,133
Payment Breakdown by Category
Food & Beverage$9,220 (95.8%)
Education$401.93 (4.2%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $9,220 | 567 | 95.8% |
| Education | $401.93 | 9 | 4.2% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Teva Pharmaceuticals USA, Inc. | $2,195 | 132 | $0 (2024) |
| Neurocrine Biosciences, Inc. | $1,487 | 63 | $0 (2024) |
| Janssen Pharmaceuticals, Inc | $1,337 | 115 | $0 (2024) |
| Indivior Inc. | $945.19 | 61 | $0 (2024) |
| Alkermes, Inc. | $867.21 | 44 | $0 (2024) |
| Otsuka America Pharmaceutical, Inc. | $768.39 | 50 | $0 (2024) |
| Sunovion Pharmaceuticals Inc. | $705.23 | 46 | $0 (2022) |
| ITI, Inc. | $522.35 | 26 | $0 (2023) |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $370.15 | 17 | $0 (2024) |
| Vanda Pharmaceuticals Inc. | $191.40 | 10 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $1,727 | 89 | Neurocrine Biosciences, Inc. ($522.52) |
| 2023 | $2,335 | 128 | Teva Pharmaceuticals USA, Inc. ($819.24) |
| 2022 | $1,543 | 97 | Neurocrine Biosciences, Inc. ($293.08) |
| 2021 | $1,636 | 92 | Janssen Pharmaceuticals, Inc ($363.93) |
| 2020 | $1,124 | 68 | Teva Pharmaceuticals USA, Inc. ($303.79) |
| 2019 | $642.43 | 42 | Teva Pharmaceuticals USA, Inc. ($209.03) |
| 2018 | $340.62 | 30 | Janssen Pharmaceuticals, Inc ($225.77) |
| 2017 | $273.10 | 30 | Janssen Pharmaceuticals, Inc ($143.71) |
All Payment Transactions
576 individual payment records from CMS Open Payments — Page 1 of 24
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/18/2024 | Neurocrine Biosciences, Inc. | INGREZZA (Drug) | Food and Beverage | In-kind items and services | $20.46 | General |
| Category: Neuropsychiatry | ||||||
| 12/18/2024 | E.R. Squibb & Sons, L.L.C. | COBENFY (Drug) | Food and Beverage | Cash or cash equivalent | $19.75 | General |
| Category: Psychiatry/Psychology | ||||||
| 12/17/2024 | Janssen Pharmaceuticals, Inc | INVEGA SUSTENNA (Drug) | Food and Beverage | In-kind items and services | $14.84 | General |
| Category: Neuroscience | ||||||
| 12/13/2024 | Teva Pharmaceuticals USA, Inc. | Austedo XR (Drug) | Food and Beverage | In-kind items and services | $20.64 | General |
| Category: Central Nervous System | ||||||
| 11/21/2024 | Alkermes, Inc. | ARISTADA (Drug), ARISTADA, ARISTADA | Food and Beverage | In-kind items and services | $15.00 | General |
| Category: CNS | ||||||
| 11/19/2024 | Otsuka America Pharmaceutical, Inc. | ABILIFY ASIMTUFII (Drug), ABILIFY MAINTENA | Food and Beverage | In-kind items and services | $23.30 | General |
| Category: PSYCHIATRY | ||||||
| 11/15/2024 | E.R. Squibb & Sons, L.L.C. | — | Food and Beverage | Cash or cash equivalent | $21.79 | General |
| 11/14/2024 | E.R. Squibb & Sons, L.L.C. | COBENFY (Drug) | Education | In-kind items and services | $27.27 | General |
| Category: Psychiatry/Psychology | ||||||
| 11/14/2024 | E.R. Squibb & Sons, L.L.C. | — | Food and Beverage | Cash or cash equivalent | $16.50 | General |
| 11/12/2024 | Neurocrine Biosciences, Inc. | INGREZZA (Drug) | Food and Beverage | In-kind items and services | $26.81 | General |
| Category: Neuropsychiatry | ||||||
| 11/08/2024 | Teva Pharmaceuticals USA, Inc. | Austedo XR (Drug) | Food and Beverage | In-kind items and services | $10.44 | General |
| Category: Central Nervous System | ||||||
| 11/06/2024 | E.R. Squibb & Sons, L.L.C. | COBENFY (Drug) | Food and Beverage | Cash or cash equivalent | $17.92 | General |
| Category: Psychiatry/Psychology | ||||||
| 11/04/2024 | Neurocrine Biosciences, Inc. | INGREZZA (Drug) | Food and Beverage | In-kind items and services | $34.40 | General |
| Category: Neuropsychiatry | ||||||
| 10/22/2024 | Teva Pharmaceuticals USA, Inc. | Austedo XR (Drug) | Food and Beverage | In-kind items and services | $1.11 | General |
| Category: Central Nervous System | ||||||
| 10/21/2024 | Neurocrine Biosciences, Inc. | INGREZZA (Drug) | Food and Beverage | In-kind items and services | $26.58 | General |
| Category: Neuropsychiatry | ||||||
| 10/16/2024 | Otsuka America Pharmaceutical, Inc. | ABILIFY ASIMTUFII (Drug), ABILIFY MAINTENA | Food and Beverage | In-kind items and services | $18.70 | General |
| Category: PSYCHIATRY | ||||||
| 10/12/2024 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | CAPLYTA (Drug) | Food and Beverage | In-kind items and services | $21.00 | General |
| Category: PSYCHIATRY | ||||||
| 10/11/2024 | Teva Pharmaceuticals USA, Inc. | Austedo XR (Drug) | Food and Beverage | In-kind items and services | $17.12 | General |
| Category: Central Nervous System | ||||||
| 10/09/2024 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | CAPLYTA (Drug) | Food and Beverage | In-kind items and services | $25.30 | General |
| Category: PSYCHIATRY | ||||||
| 10/06/2024 | Vanda Pharmaceuticals Inc. | FANAPT (Drug) | Food and Beverage | In-kind items and services | $16.15 | General |
| Category: SCHIZOPHRENIA | ||||||
| 10/04/2024 | Neurocrine Biosciences, Inc. | INGREZZA (Drug) | Food and Beverage | In-kind items and services | $26.81 | General |
| Category: Neuropsychiatry | ||||||
| 10/01/2024 | Alkermes, Inc. | ARISTADA (Drug), ARISTADA, ARISTADA | Food and Beverage | In-kind items and services | $14.65 | General |
| Category: CNS | ||||||
| 09/30/2024 | Neurocrine Biosciences, Inc. | INGREZZA (Drug) | Food and Beverage | In-kind items and services | $26.14 | General |
| Category: Neuropsychiatry | ||||||
| 09/27/2024 | Teva Pharmaceuticals USA, Inc. | UZEDY (Drug) | Food and Beverage | In-kind items and services | $11.60 | General |
| Category: Neurology | ||||||
| 09/16/2024 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | CAPLYTA (Drug) | Food and Beverage | In-kind items and services | $23.79 | General |
| Category: PSYCHIATRY | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 4 | 140 | 1,869 | $194,825 | $121,425 |
| 2022 | 4 | 176 | 3,582 | $369,600 | $210,564 |
| 2021 | 4 | 190 | 3,258 | $339,500 | $198,936 |
| 2020 | 4 | 278 | 3,056 | $323,450 | $183,207 |
Total Patients
784
Total Services
11,765
Medicare Billing
$714,133
Procedure Codes
16
All Medicare Procedures & Services
16 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 53 | 1,765 | $176,500 | $111,831 | 63.4% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 34 | 44 | $7,625 | $4,408 | 57.8% |
| 99238 | Hospital discharge day management, 30 minutes or less | Facility | 2023 | 36 | 43 | $6,450 | $2,804 | 43.5% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 17 | 17 | $4,250 | $2,381 | 56.0% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 61 | 3,418 | $341,800 | $195,341 | 57.2% |
| 99222 | Initial hospital inpatient care per day, typically 50 minutes | Facility | 2022 | 36 | 63 | $9,450 | $6,223 | 65.8% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 32 | 32 | $8,000 | $5,036 | 63.0% |
| 99238 | Hospital discharge day management, 30 minutes or less | Facility | 2022 | 47 | 69 | $10,350 | $3,964 | 38.3% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 65 | 3,050 | $305,000 | $178,738 | 58.6% |
| 99222 | Initial hospital inpatient care, typically 50 minutes per day | Facility | 2021 | 40 | 91 | $13,650 | $9,803 | 71.8% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 33 | 33 | $8,250 | $5,418 | 65.7% |
| 99238 | Hospital discharge day management, 30 minutes or less | Facility | 2021 | 52 | 84 | $12,600 | $4,976 | 39.5% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2020 | 96 | 2,815 | $281,500 | $159,683 | 56.7% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2020 | 57 | 58 | $14,500 | $9,016 | 62.2% |
| 99222 | Initial hospital inpatient care, typically 50 minutes per day | Facility | 2020 | 52 | 84 | $12,600 | $8,835 | 70.1% |
| 99238 | Hospital discharge day management, 30 minutes or less | Facility | 2020 | 73 | 99 | $14,850 | $5,674 | 38.2% |
About Dr. Gabriella Pasztor, M.D
Dr. Gabriella Pasztor, M.D is a Psychiatry healthcare provider based in Sugar Land, Texas. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/14/2007. The National Provider Identifier (NPI) number assigned to this provider is 1659575231.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Gabriella Pasztor, M.D has received a total of $9,622 in payments from pharmaceutical and medical device companies, with $1,727 received in 2024. These payments were reported across 576 transactions from 15 companies. The most common payment nature is "Food and Beverage" ($9,220).
As a Medicare-enrolled provider, Pasztor has provided services to 784 Medicare beneficiaries, totaling 11,765 services with total Medicare billing of $714,133. Data is available for 4 years (2020–2023), covering 16 distinct procedure/service records.
Ad
Practice Information
- Specialty Psychiatry
- Location Sugar Land, TX
- Active Since 06/14/2007
- Last Updated 11/14/2013
- Taxonomy Code 2084P0800X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1659575231
Products in Payments
- INGREZZA (Drug) $1,487
- INVEGA SUSTENNA (Drug) $1,157
- PERSERIS (Drug) $945.19
- Austedo XR (Drug) $936.11
- AUSTEDO (Drug) $930.53
- CAPLYTA (Drug) $892.50
- ARISTADA (Drug) $845.84
- LATUDA (Drug) $705.23
- ABILIFY MAINTENA (Drug) $392.99
- REXULTI (Drug) $314.94
- FANAPT (Drug) $113.64
- INVEGA TRINZA (Drug) $104.13
- ABILIFY ASIMTUFII (Drug) $81.88
- HETLIOZ (Drug) $77.76
- COBENFY (Drug) $64.94
- SECUADO (Drug) $54.76
- SPRAVATO (Drug) $34.83
- LYBALVI (Drug) $21.37
- Dayvigo (Drug) $19.88
- Auvelity (Drug) $17.20
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Psychiatry Doctors in Sugar Land
Dr. Deena Gandhi, Md, MD
Psychiatry — Payments: $98,489
Psychiatry $98,489
Dr. Kimberly Cress, M.d, M.D
Psychiatry — Payments: $8,851
Psychiatry $8,851
Dr. Diana Collins, M.d, M.D
Psychiatry — Payments: $7,820
Psychiatry $7,820
Penny Chow, Md, MD
Psychiatry — Payments: $7,529
Psychiatry $7,529
Dr. Mudassar Tariq, Md, MD
Psychiatry — Payments: $6,717
Psychiatry $6,717
Dr. Huma Qadir, M.d, M.D
Psychiatry — Payments: $5,450
Psychiatry $5,450